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Abstract Following ligand-promoted internalization the human
type 2 vasopressin receptor (hV2R) is not recycled to the cell
surface after removal of the agonist. A retention motif consist-
ing of a serine triplet present in the cytoplasmic tail was pre-
viously found to require for retention, but serine 357, and threo-
nines 359, 360 located upstream were not examined. Evidence is
now presented that substitution of these amino acids did not
change V2 internalization although it reduced the levels of ar-
ginine vasopressin (AVP)-induced phosphorylation as compared
to the wild type (WT). Contrary to the WT hV2R, these mutant
receptors were recycled to the cell surface after a 2 h incubation
in the absence of AVP identifying these changed residues as
additional members of the retention motif of the hV2R.
. 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Arginine vasopressin (AVP) is a peptide hormone that reg-
ulates water homeostasis by binding to speci¢c receptors of
the G protein-coupled receptor (GPCR) superfamily [1]. As is
the case for many GPCRs the type 2 vasopressin receptor
(V2R) itself is rapidly phosphorylated after activation by
AVP by a G protein-coupled receptor kinase (GRK) [2].
Receptor phosphorylation has been shown to accelerate re-
ceptor uncoupling from G proteins and initiate cell desensiti-
zation to subsequent stimulation by the same agonist [3]. For
most receptors, this process is reversible. Resensitization in-
volves internalization of the phosphorylated receptor followed
by ligand dissociation and loss of the incorporated phosphates
[4]. The dephosphorylated receptors return to the cell surface
ready to commence another round of cellular response. A few
members of the GPCR family, such as the endothelin B and
the protease-activated receptors [5^8], are sorted to lysosomes
for degradation instead of recycling to the cell surface.
Although the human V2R (hV2R) is not recycled to the cell
surface after ligand-induced internalization, it is not targeted
to lysosomes as the protein remains intact and phosphorylated
hours after removal of the agonist [9].
The hV2R has nine amino acids susceptible to phosphory-
lation downstream of the Asp-Glu motif recognized by GRKs
[10]. Sequential deletion of the last residues led to a progres-
sive decrease in the level of phosphorylation and conferred
recycling to the truncated receptor. Site-directed mutagenesis
of serines 362, 363, or 364 by alanine revealed the importance
of this cluster in the retention phenomenon since all the mu-
tant proteins recycled [11].
To verify whether the ‘retention’ motif is limited to these
three serines or includes other residues susceptible to phos-
phorylation, serine 357 and threonines 359 and 360 were in-
dividually substituted by alanine (Fig. 1A) and the mutant
hV2Rs examined for level of phosphorylation, internalization
and recycling.
2. Materials and methods
2.1. Materials
Tissue culture supplies were from Life Technologies, Inc., Gaithers-
burg, MD, USA. Chemicals were from Fisher Scienti¢c, Pittsburgh,
PA, USA. H3 32PO4 (speci¢c activity: 8500^9120 Ci/mmol) and
[3H]AVP (speci¢c activity: s 60 Ci/mmol) were from DuPont NEN,
Boston, MA, USA.
2.2. Mutagenesis of the hV2R
A previously described polymerase chain reaction (PCR)-based
methodology was used to introduce the mutations into the cDNA
encoding for the wild-type (WT) hV2R [11].
2.3. Cell culture and transfection
HEK293T cells were grown in Dulbecco’s modi¢ed Eagle’s medium
(DMEM) high glucose containing 10% heat-inactivated fetal bovine
serum (FBS), 50 units/ml of penicillin and 50 mg/ml of streptomycin.
For transient expression of the V2R, cells were plated at 3.5U106/100
mm dish and transfected the following day as previously described
[11]. Cells were assayed 2 days later.
2.4. Receptor phosphorylation
Cells seeded in six-well plates (V6U105 cells/well) previously
coated with polylysine (Sigma) were labeled with 100 WCi/well of
H3 32PO4 for 2 h at 37‡C. AVP was added to make the medium
100 nM AVP and the incubation continued at 37‡C for the times
indicated. Cells were then chilled on ice and processed as previously
described for receptor immunoprecipitation with an antibody raised
against the cytoplasmic tail of the hV2R [2]. The precipitated proteins
were separated by electrophoresis on a 10% sodium dodecyl sulfate^
polyacrylamide gel (SDS^PAGE), the gel was dried and the bands
were visualized by autoradiography and quanti¢ed using the Opti-
Quant1 software from the Cyclone1 Storage Phosphor Scanner
(Packard Instrument Company, Inc.) system. Gel loading was normal-
ized for cell surface expression determined by [3H]AVP binding.
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2.5. Binding assay
Transfected cells seeded in polylysine-treated 24-well plates at a
density of 1.5U105 cells/well were washed twice with ice-cold D-phos-
phate-bu¡ered saline (PBS) and exposed to 25 nM of [3H]AVP in 250
Wl of D-PBS containing 2% bovine serum albumin (BSA) to determine
the number of binding sites/cell as previously described. Non-speci¢c
binding was determined in the presence of 10 WM unlabeled AVP.
Binding experiments were performed in triplicate.
2.6. V2R sequestration and recycling
Cells were plated in polylysine-treated 24-well plates at a density of
1.5U105 cells/well 24 h after transfection. The following day the cells
were challenged with 100 nM AVP in DMEM high glucose containing
1% BSA and 20 mM HEPES (pH 7.4) for 20 min at 37‡C. Plates were
then chilled on crushed ice and the cells washed twice with cold
D-PBS, twice with ice-cold 150 mM NaCl/5 mM acetic acid and
¢nally three times with D-PBS. 500 Wl of DMEM/BSA/HEPES solu-
tion was added to each well and the cells were returned to 37‡C for
the indicated time. The number of receptors on the cell surface was
then evaluated by [3H]AVP binding as described above. Results are
expressed as a percent of the number of receptor sites present before
hormone treatment. Data are presented as meansPS.E.M. of at least
three independent experiments.
3. Results
To determine whether the putative phosphorylation sites
T360, T359 and S357 of the hV2R contribute to the retention
motif, these residues were individually substituted by alanine
and the internalization and recycling of the resulting mutant
receptors were examined. The WT and S363A V2Rs were used
as reference in these experiments. As it was the case for all
mutations and truncations modifying the last 20 amino acids
of the V2R, the mutant proteins were expressed at the same
level as the wild-type receptor and its binding and coupling to
Gs remained unchanged [2,11].
The impact of the mutations on internalization and recy-
cling was examined ¢rst. Cells expressing the WT receptor lost
37% of the surface receptors after a 20 min exposure to 100
nM AVP at 37‡C, and under the same conditions the same
fraction of surface receptor was lost for all the hV2R mutants.
Following the removal of the external AVP, acid wash, and
the addition of fresh medium, plates were returned to the
37‡C incubator for di¡erent times. As seen before, after a
2 h incubation there was no change on the abundance of
WT V2R on the cell surface, whereas all the mutant V2Rs
exhibited recycling after the agonist was removed. The S363A
V2R receptor abundance returned to V95% of the original
value, the S357A and T360A V2Rs recovered 84P6% and
86P 4% of binding sites, respectively, whereas a lower recov-
ery was observed for the T359A mutant receptor. For this
protein, the abundance returned only to 71P 4% of the sites
present on non-treated cells. Data from these experiments are
illustrated in Fig. 2 and summarized in Table 1.
The extent and time course of phosphorylation of the re-
cycling mutant proteins were examined next, the results are
shown in Fig. 3. The data are expressed as percentage of the
level of phosphorylation obtained for the WT receptor after
30 min of exposure to AVP. To compare the levels of phos-
phorylation of the proteins, the amount of immunoprecipi-
tated labeled receptors loaded in the gels was normalized for
di¡erences in cell surface expression, as assessed by [3H]AVP
binding done in parallel for each transfection. The WT and
mutant V2Rs were rapidly phosphorylated in the presence of
AVP, the level of phosphorylation reaching a plateau between
5 and 15 min and remaining stable afterwards. The results
suggested that the variation in the level of phosphorylation
is dictated by the identity of the altered site; no evidence of
Fig. 1. Schematic representation of the hV2R. The amino composi-
tion of a section of the cytoplasmic tail containing the substituted
residues (on a black background) is represented next to the recep-
tor. The substitution S363A in the triple serine sequence has been
described previously [10]. In this study, the residues 357, 359 and
360 were individually substituted by alanine and compared to the
WT and S363A mutant V2Rs.
Fig. 2. AVP-induced sequestration and recovery of WT and mutant
hV2Rs. Receptor density on the cell surface was evaluated by
[3H]AVP binding on HEK293T transiently expressing the WT
(F, n=7), S363A (a, n=5), S357A (8, n=4), T359A (b, n=4) or
T360A (O, n=4) V2Rs. After a treatment with 100 nM AVP for
20 min at 37‡C, cells were washed and incubated at 37‡C in com-
plete medium for the indicated recovery time. [3H]AVP binding was
performed as described in Section 2. Results (meanPS.D.) are ex-
pressed as percent of the number of receptor sites present before
hormone treatment.
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rapid dephosphorylation induced by the mutations was de-
tected (Table 1). The reduction in maximal phosphorylation
for the mutant receptors re£ected the loss of more than one
phosphate acceptor site, suggesting that phosphorylation of
those residues was required for the subsequent phosphory-
lation of other acceptor sites. Hierarchy of phosphorylation
sites has also been reported for the A3 adenosine receptor and
the N-formyl peptide receptor [12,13]. The T359A V2R
showed the greatest reduction in phosphate incorporation
although, as mentioned previously, its recycling to the cell
surface was the least e¡ective.
It has been shown that recycling of the human N-opioid
receptor is completely suppressed by treatment of the cells
with 10 nM okadaic acid, a phosphatase 2A inhibitor, sup-
porting the hypothesis that dephosphorylation is necessary for
the recycling of certain GPCRs [14]. Similar treatments were
carried out with cells expressing the S363A V2R mutant with
10 and 50 nM okadaic acid, but no alteration of recycling was
observed (data not shown). As shown in Fig. 4 and consistent
with the recycling data, the phosphatase inhibitor did not
delay the cleavage of radioactive phosphate from the immu-
noprecipitated phosphorylated receptor, suggesting that phos-
phatases other than protein phosphatase 2A participate in this
process.
Table 1
AVP-induced sequestration and phosphorylation of WT and mutant V2 receptors
V2 receptor Cell surface receptors (%) Phosphate incorporated (%)
20 min+AVP 20 min+AVP 30 min+AVP
120 min3AVP
WT 63P3 (7) 66P 3 (7) 100 (9)
S357A 50P 4 (4) 84P 6 (4) 85P 7 (3)
T359A 54P 3 (4) 71P 4 (4) 68P 4 (4)
T360A 48P 1 (4) 86P 4 (4) 83P 6 (5)
S363A 49P 2 (5) 95P 2 (5) 90P 5 (3)
WT, human 64P 5 (7) 63P 4 (4)
Cell surface receptors are expressed as percentage of the number of AVP binding sites present on non-stimulated cells. Receptor sequestration
and kinetics of recovery without AVP are presented in Figs. 2A, B and 4. The level of phosphorylation is expressed as percentage of 32PO4 in-
corporation observed for the WT receptor after a 30 min exposure to 100 nM AVP. Kinetics of phosphorylation are presented in Fig. 3A and
B. The numbers between parentheses indicate the number of experiments performed.
Fig. 3. AVP-induced phosphorylation of WT and mutant hV2R.
Receptor phosphorylation was examined in HEK293T cells tran-
siently expressing the WT (F, n=9), S363A (R, n=3), S357A
(8, n=3), T359A (b, n=4) or T360A (E, n=5) V2Rs. Cells were
labeled with inorganic 32P and stimulated for the indicated time
with 100 nM AVP at 37‡C. Receptor proteins were immunopuri¢ed
as described in Section 2, resolved by SDS^PAGE, and analyzed for
incorporated radioactivity using the OptiQuant1 software from the
Cyclone1 Storage Phosphor Scanner system. The background was
determined for each lane and subtracted from the value obtained
from the receptor band. The results (meanPS.D.) were normalized
for cell surface expression and are expressed as a percentage of the
value obtained at 30 min with the WT V2R.
Dephosphorylation of the S363A-V2R
0.17% DMSO 50 nM Okadaic acid
in 0.17% DMSO
100 nM AVP
Time after AVP
(min)
- - - -
--
+ + + + + + + + + + + +
20 60 120 20 60 120
Fig. 4. Dephosphorylation rate of S363A mutant V2R. Cell labeling
and phosphorylation of the S363A V2R was carried out as de-
scribed in the legend of Fig. 3 with the exception that throughout
the experiment the cell medium contained 50 nM okadaic acid in
0.17% dimethylsulfoxide (DMSO). The control cells were exposed to
0.017% DMSO alone. After 20 min exposure to 100 nM AVP at
37‡C, the cells were acid washed, neutralized and returned to the in-
cubator with fresh medium containing either DMSO or okadaic
acid/DMSO. At the indicated times cells were harvested and the re-
ceptor protein immunopuri¢ed and analyzed as described in the
legend of Fig. 3.
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4. Discussion
The phosphorylation acceptor sites of the hV2R were pre-
viously identi¢ed as the nine serines and threonines that fol-
low the two negatively charged amino acids present at the
carboxyl terminus [2,11]. Among these phosphorylated sites
the serine triplet was found to be required for receptor reten-
tion inside the cell, evidence presented here identi¢ed the three
amino acids susceptible to phosphorylation by GRK located
upstream from the serine triplet as additional components of
the hV2R retention signal. Substitution of serine 350 of the
hV2R for alanine did not alter receptor recycling, indicating
that this amino acid is not part of the motif (data not shown),
and that only the phosphorylation acceptor sites immediately
downstream from the two negatively charged amino acids are
involved in receptor retention (see Fig. 1). The mutant T359A
hV2R displayed the lowest level of phosphate incorporation
and of return to the cell surface (Table 1) suggesting that the
identity of the phosphorylated sites rather than their number
determines the recycling behavior.
It has been suggested based on cell imaging data, that a
prolonged interaction between the V2R and another protein,
possibly of the arrestin family, could prevent dephosphoryla-
tion and block receptor recycling, but the biochemical proof
for this hypothesis is still missing [15]. We recently reported
that the non-recycling hV2R and the recycling S363A hV2R
accumulate in the same perinuclear recycling compartment. In
both cases arrestin(s) co-localized with the receptor in this
organelle, indicating that neither the identity of the compart-
ment, nor prolonged association or co-migration with arres-
tin, were responsible for the trapping of the WT hV2R [16].
This observation did not rule out the participation of arrestin
in receptor trapping, but it clearly established that its pro-
longed interaction with the V2R did not by itself retain the
receptor inside the cell. Studies carried out by other laborato-
ries have assigned the trapping activity to the serine triplet
[15], albeit the data presented indicate that additional amino
acids play a role in the retention phenomenon.
It is di⁄cult at the moment to speculate about the univer-
sality of the trapping factors or the biological implications of
GPCR retention. The M2 acetylcholine muscarinic is another
example of a receptor that does not recycle after ligand-in-
duced internalization [17,18], although the amino acid com-
position of the third intracellular loop responsible for inter-
nalization reveals similarities but no signi¢cant identity with
the hV2R retention signal. Whole cell binding assays per-
formed before and after ligand-promoted internalization
with [3H]quinuclidyl benzylate, a cell permeable antagonist
of the M2 receptor, indicated that the total number of recep-
tors per cell did not change signi¢cantly after prolonged treat-
ment with carbachol, although whole cell binding with
[3H]-N-methylscopolamine, a non-cell permeant antagonist of
the M2 receptor, detected a 80% loss of cell surface receptors.
This indirect assessment of the fate of the internalized M2
receptor protein suggests that the trapped receptor remains
intact and able to bind its ligand inside the cell [18]. Similar
results were also obtained with the acetylcholine M3 musca-
rinic receptor endogenously expressed in SH-SY5Y human
neuroblastoma cells [19]. Further studies on the hV2R and
the muscarinic receptors could lead to the discovery of a
new family of GPCR-interacting proteins or ascribe receptor
retention properties to an already characterized protein, a
process that will be advanced by the accurate de¢nition of
the retention signal.
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